StockData
Kiniksa Pharmaceuticals International, plc logo

Kiniksa Pharmaceuticals International, plc (KNSA) stock

KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30469% above fair value
$95.11+0.88 (+0.93%)

Close on Nov 17, 2026Market cap $14.95BP/E 73.2Yield –

Kiniksa Pharmaceuticals International total assets

Total assets on the balance sheet at the end of each period.

Kiniksa Pharmaceuticals International's total assets was $983.24M at Sep 30, 2026. For fiscal 2025 it was $763.63M, up 31.5% from the year before. The highest annual figure on record is $763.63M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$763.63M+31.5%
FY2024Dec 31, 2024$580.55M+10.3%
FY2023Dec 31, 2023$526.32M+14.5%
FY2022Dec 31, 2022$459.67M+97.5%
FY2021Dec 31, 2021$232.80M-33.4%
FY2020Dec 31, 2020$349.46M+37.3%
FY2019Dec 31, 2019$254.53M-20.9%
FY2018Dec 31, 2018$321.97M+577.9%
FY2017Dec 31, 2017$47.49M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$983.24M+38.0%
Q2 FY2026Jun 30, 2026$896.11M+35.5%
Q1 FY2026Mar 31, 2026$825.28M+37.7%
Q4 FY2025Dec 31, 2025$763.63M+31.5%
Q3 FY2025Sep 30, 2025$712.33M+28.3%
Q2 FY2025Jun 30, 2025$661.15M+21.9%
Q1 FY2025Mar 31, 2025$599.33M+15.3%
Q4 FY2024Dec 31, 2024$580.55M+10.3%
Q3 FY2024Sep 30, 2024$555.30M+15.0%
Q2 FY2024Jun 30, 2024$542.43M+12.0%
Q1 FY2024Mar 31, 2024$519.67M+17.3%
Q4 FY2023Dec 31, 2023$526.32M+14.5%
Q3 FY2023Sep 30, 2023$483.06M+5.0%
Q2 FY2023Jun 30, 2023$484.33M+130.0%
Q1 FY2023Mar 31, 2023$442.86M+91.7%
Q4 FY2022Dec 31, 2022$459.67M+97.5%
Q3 FY2022Sep 30, 2022$459.95M+81.9%
Q2 FY2022Jun 30, 2022$210.58M-24.6%
Q1 FY2022Mar 31, 2022$230.97M-25.8%
Q4 FY2021Dec 31, 2021$232.80M-33.4%
Q3 FY2021Sep 30, 2021$252.86M-34.2%
Q2 FY2021Jun 30, 2021$279.21M+2.9%
Q1 FY2021Mar 31, 2021$311.16M+37.6%
Q4 FY2020Dec 31, 2020$349.46M+37.3%
Q3 FY2020Sep 30, 2020$384.41M+36.4%
Q2 FY2020Jun 30, 2020$271.44M-11.9%
Q1 FY2020Mar 31, 2020$226.11M-34.7%
Q4 FY2019Dec 31, 2019$254.53M-20.9%
Q3 FY2019Sep 30, 2019$281.81M-18.8%
Q2 FY2019Jun 30, 2019$308.14M-15.6%
Q1 FY2019Mar 31, 2019$346.16M+628.9%
Q4 FY2018Dec 31, 2018$321.97M–
Q3 FY2018Sep 30, 2018$347.10M–
Q2 FY2018Jun 30, 2018$365.13M–
Q4 FY2017Dec 31, 2017$47.49M–

More Kiniksa Pharmaceuticals International figures

See a number that looks wrong?